For Investors

Global Kinetics Corporation is a commercial-stage digital health company revolutionising the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments.

The company’s Parkinson's KinetiGraph® (PKG® or Personal KinetiGraph® as it is known in the USA) is a patient-friendly, algorithm-based system that records patients’ movements over the course of several days and creates data-driven reports that empowers more personalised treatment and management decisions—ultimately leading to a higher quality of life for patients.

The PKG® system is being used in clinics across the U.S., Europe and Asia Pacific, enabling better clinical outcomes and reducing health care costs across the Parkinson’s disease continuum. Global Kinetics Corporation continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure efficacy of new and advanced therapies for one of the world’s most widespread movement disorders.

Name Global Kinetics Corporation Limited (GKC)
Status Privately-held Australian company 
Industry/Sector Digital health/Parkinson's disease and other movement disorders
Established  July 2007 in Melbourne, Australia
Locations Australia (headquarters), USA and European Union
Personnel 42 FTE (Australia 19, USA 7, European Union 12)
Financings Five private rounds, all at progressively higher prices


Treat to Target trial announcement

GKC has successfully secured funding from the high profile and leading international funder in Parkinson's - The Michael J. Fox Foundation as well as the Shake It Up Australia Foundation and Parkinson's Victoria, to support a global trial to evaluate the use of objective targets to guide the treatment and management of Parkinson's disease. Read press release here.